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On behalf of everyone at the Juvenile Diabetes Cure Alliance, we are pleased to pres-
ent State of the Cure 2013, our second annual review of progress toward a cure for type 
1 diabetes. We’ve taken a comprehensive look back at cure-related developments in 
2013 so that we can outline what needs to happen in the next twelve months in order 
to achieve a Practical Cure for type 1 by 2025.
The State of the Cure covers four main topics related to Practical Cure progress. First, 
we assess the significant impact that type 1 has on many Americans. Of particular note 
here is donors’ strong support for a Practical Cure. Second, our review of Practical Cure 
research reveals that while medical science has made little material progress toward 
a type 1 cure in the past year, there are a few encouraging developments which can 
provide opportunities for future progress. Third, our analysis of managerial practices 
at the major diabetes non-profits finds a distinct misalignment between donor wishes 
and the non-profits’ actual use of donor contributions. Finally, we recommend action 
steps that donors can take to drive substantive change in 2014.
At just a little over two years old, the JDCA remains deeply committed to bringing about 
a Practical Cure for type 1 diabetes by 2025. Over the past year we have published 17 
reports and appeared in a variety of publications, including The Wall Street Journal 
and The Chronicle of Philanthropy. Based upon your input, we have also launched a 
high-impact donor advisory service and influenced millions of dollars in philanthropic 
giving for type 1. 
The year ahead will take us into new territory. We will expand our coverage of institu-
tions that take part in diabetes research, and amplify our advocacy for a Practical Cure 
through a larger media presence. We hope that you will use the State of the Cure 2013 
to inform and guide your philanthropic decisions throughout the upcoming year. 
Thank you for your continued support of the JDCA and a Practical Cure for type 1.
Aaron Gorin 
Director of Research Analysis
Phil Shaw
General Manager    
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Over 5 million Americans are directly impacted by type 1 diabetes. At least one million 
are living with the disease, while another 4 million live in households that are manag-
ing type 1. 1
Type 1 diabetes is an autoimmune disease in which the body cannot produce insulin 
because it has destroyed its pancreatic beta cells. Consequently, people with type 1 di-
abetes must manually administer insulin, either through injections or an insulin pump. 
Management is a daily and hourly task because blood sugar levels are affected by a 
number of often unpredictable factors, including meals, exercise, illness, and stress. It 
takes countless hours of planning and monitoring to maintain optimal A1c levels.
Mounting Costs
In addition to medical, emotional, and social burdens, type 1 also inflicts significant 
financial costs on individuals and the national healthcare system. Roughly $14.4 billion 
dollars is spent per year in the United States to provide medical care for type 1, funded 
primarily through insurance and government programs. This figure breaks down into 
$6.9 billion in out-of-pocket costs plus third-party payments that cover hospital and 
doctor visits, insulin, prescription drugs, medical supplies, home health provider ser-
vices, and vision and dental care. The other $7.5 billion is attributable to lost income 
from missed work days and lower productivity. 2
 
Americans with diabetes incur medical expenses significantly higher than those with-
out diabetes. Annual medical costs for a person with type 1 average around $9,900, 
which is nearly three times the average for people without type 1. In addition, manag-
ing type 1 becomes more costly later in life because the longer that one lives with the 
disease, the greater the chances of developing complications.3
Type 1 Diabetes Cure Progress
During the past half century there have been strong advances in treatments for type 1 
but little tangible progress toward a cure. Innovations in the design of insulin pumps, 
more accurate testing tools, and faster acting insulin have made it easier to accurately 
monitor blood glucose levels and to administer insulin. Careful attention to diet and 
exercise, and disciplined daily management can lessen the risk of complications and 
extend life expectancy. But despite these treatment advances, a cure remains elusive. 
 
The majority of cure research focuses on ideal solutions, or an “Idealized Cure.” While 
some exciting avenues of research are being pursued, results from most of these path-
ways will require many decades to develop and are unlikely to be available for the 
generation of people who are currently living with type 1.
This report addresses the number one concern of donors: progress toward a cure for 
the current generation of people with type 1. The next section elaborates on the defi-
nition of a Practical Cure and the importance of a 2025 target date.
1 JDCA report, “The Size of the Population Impacted by Type 1 Diabetes,” Aug 2013. 
2 Betty Tao, et al, “Estimating the Cost of Type 1 Diabetes in the U.S.: A Propensity Score Matching Method,” PLos One 5(7): 2010.
3 ibid.
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3A Practical Cure for type 1 diabetes is any solution that 1) enables people with estab-
lished type 1 to have a near normal lifestyle, and 2) has the potential to be widely 
available by 2025. 
A Practical Cure is defined in the language of patients rather than medical science. 
Using non-scientific language keeps the objective simple and focused, and enables the 
greatest possible range of scientific solutions. Characteristics of a Practical Cure directly 
reflect the wishes and desires of the people living with type 1 and their families, which 
they have made clear over several years of interviews and survey research. There are 
three characteristics that set our definition of a Practical Cure apart. 
1. Outcome based rather than scientific
2. Potential to be widely available by 2025 
  
3. Contrasts a practical solution versus a perfect or idealized one
III. What Is Practical Cure Research? 
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Practical Cure Characteristics
An Idealized Cure, which is commonly presented as “the cure” for type 1, is pred-
icated upon entirely eliminating the disease. In contrast, a Practical Cure is much 
wider in scope and includes any solution that frees a person with type 1 from the 
daily burden of the disease and the worry of complications. While a perfect solu-
tion would be welcomed, the scientific community has pursued one without suc-
cess for over a century. Even now, Idealized Cure research is at such an early stage 
of conceptual development that it is unlikely to deliver a cure in time to benefit 
anyone who is currently living with type 1. The next section illustrates that donors 
expect a cure to be available much sooner. 
The date is a target, not a promise. Donors overwhelmingly want to change the lives 
of people living with diabetes today. Setting a target date for a cure ensures that we 
are focusing on solutions that can impact this generation. Without such a time goal 
there is no mechanism to prioritize projects that have the best chance of delivering 
results sooner over projects that are more likely to produce results over a longer 
time frame.  
In advocating for a Practical Cure, the JDCA does not favor any particular scientific 
approach to achieve the desired outcome. We track several research approaches 
that have the potential to deliver a Practical Cure by 2025. (The different Practical 
Cure research platforms will be discussed in Section VI.)  
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The JDCA has conducted eight surveys of the type 1 diabetes donor community over 
the last two years to gauge donors’ expectations, priorities, and attitudes about cure 
progress. In all cases we sought to accurately track and disseminate donor and com-
munity sentiment in the hope of improving alignment between donor wishes and the 
non-profits’ funding priorities. 
The surveys were conducted by a third party and were carefully monitored to follow 
best practices of market research and survey design. These surveys collectively pooled 
answers from over 2,000 respondents. The results were statistically significant, and the 
margin of error never exceeded 10%.  
Donor Expectations
The JDCA surveys provide three key learnings: 1) donors expect a cure in the near 
future; 2) they would prefer to fund projects that could produce a cure sooner rather 
than later; 3) they are willing to give to Practical Cure research if that option was made 
easily available. In fact, nine out of ten donors prioritize funding Practical Cure research 
over funding Idealized Cure research.
Many people with type 1 diabetes have been hearing that a cure is imminent since 
they were diagnosed, even if that diagnosis was decades ago. Expectations are stoked 
by the flurry of news stories about reversing type 1 diabetes in mice, research progress 
touted as “on the cusp of major breakthrough,” and fundraising events that promise to 
find a cure. As shown in Exhibit 3, seven out of ten donors believe that a cure will actu-
ally arrive in the next ten years, and nearly all donors want a cure in the next decade. 
Given the value and expectation placed on delivering results within the next decade, it 
is no surprise that donors nearly universally state that they would much prefer to fund 
projects that may deliver results in a shorter timeline than projects that are on a much 
longer time horizon. 
Opportunity for Non-Profits to Expand Cure Funding 
Donors value the pursuit of a Practical Cure to such a degree that they are willing to 
give expressly for this purpose. Exhibit 5 shows that eight out of ten active donors 
state that they would either “definitely” or “probably” donate specifically to Practi-
cal Cure research if that option was made easily available. The concept of a Practical 
Cure is even appealing enough that a full third of lapsed donors who have not given in 
several years would consider once again becoming active contributors to the diabetes 
non-profits if their funds were applied to Practical Cure research.  
Identifying projects that target the outcomes of a Practical Cure and committing donor 
contributions to that purpose will drive an increase in donations. Active donors are 
prepared to contribute for a Practical Cure, and a good percentage of lapsed donors 
will be motivated to renew giving as well. Unfortunately, the non-profits only pursue 
Practical Cure research to a limited degree, as we discuss in the next section. 
IV. Donor Attitudes           
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Which cure outcome would you prefer? 
When do you think a type 1 cure will arrive?
SOURCE: JDCA proprietary survey, Donor Attitudes and Behaviors, May  
2013
Would you donate to a Practical Cure if           
you had the option? (% of Respondents)
SOURCE: JDCA proprietary survey, Donor Attitudes and Behaviors, 
May  2013
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The JDCA finds that only two cents of every donor dollar were directed to Practical 
Cure research projects, as shown in Exhibit 6. We base our analysis of the non-profits’ 
cure research funding on publicly available information, including each organization’s 
annual report, Form 990, audited financial statements, official website, and other pub-
lications.
The chart below demonstrates the percentage of donor contributions that each 
non-profit allocates to Practical Cure research. Notably, the ADA and Joslin devote 
none of their budgets to Practical Cure research. While JDRF funded the most Practical 
Cure research in absolute dollars, its $6 million allocation represents only 3% of total 
donor contributions. The DRIF’s $3 million allocation represents a larger 27% of its 
donor contributions. 
    
A transformative shift in the cure research strategies of the non-profits is needed 
to create a more balanced research portfolio. If the non-profits are to spend donor 
money according to donor wishes, a higher percentage of donor contributions should 
be allocated to Practical Cure research. 
Focusing a larger portion of the total research portfolio on Practical Cure projects in-
creases the probability of developing a Practical Cure by 2025. We recognize that re-
search targeting complications, glucose control, and prevention has value to donors 
and we are not suggesting that such research should be abandoned. Ideally, the JDCA 
would like to see all of the non-profits direct at least 25% of donor contributions to a 
Practical Cure research initiative. Of the $398 million in donations to the four major 
non-profits, only $9 million was directed to Practical Cure research projects (2%). In-
creasing that from 2% to 25% would translate to nearly $100 million in total Practical 
Cure research funding.
We believe that while the 25% target is a long term goal, Practical Cure funding is so 
low right now that any budgetary shift toward Practical Cure work would have a signif-
icant impact. Each incremental 1% of overall donor contributions, or $4 million, would 
mean an almost 50% increase from the current level of funding for Practical Cure re-
search, which underscores the importance of starting the shift in capital allocation pri-
orities as soon as possible. 
Until the non-profits proactively create a Practical Cure Research initiative, donors 
have the ability to increase funding for this work by stipulating that their donation be 
used only for Practical Cure research. In the following section we outline the various 
research platforms that donors who seek a Practical Cure could support.
 V. Funding for Practical Cure Research 
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As shown in Exhibit 9 below, the JDCA has identified four current research approaches 
that may result in a Practical Cure: islet transplantation, pharmacology, mechanical 
devices, and cell retraining. As mentioned in Section II, the JDCA is neutral with respect 
to scientific approaches. The fundamental differences between the platforms concern 
only the method by which the targeted outcomes are achieved rather than the viability 
of the scientific approach. The JDCA does not forecast the likelihood of any one partic-
ular platform’s success. 
Among the four current approaches, human clinical trials are currently underway for 
research projects that target a Practical Cure via islet cell transplantation, cell retrain-
ing, and pharmacology. We discuss these projects in Section VII. There are no medical 
devices that currently meet all of the criteria for a Practical Cure, but a future iteration 
may do so, as medical devices can potentially progress to market faster than pharma-
ceutical approaches.
Given the ten or more years that it could take for a project to advance through pre-clin-
ical and clinical testing and then receive final U.S. FDA approval, a potential Practical 
Cure would need to advance to at least the pre-clinical stage of development fairly 
soon in order to be market ready by 2025. In the next section, we review the major 
human clinical trials that have the potential to achieve a Practical Cure.
 VI. Practical Cure Research Platforms




Practical Cure Platforms 
Islet Cell Transplantation 
(Inserting health beta cells inside the body and 
enabling them to regenerate and flourish)
 Site selection (optimal location for transplantation into 
body) 
 Cell protection (e.g. advanced encapsulation,  
immunosuppressant with minimal side effects) 
 Cell health  (e.g. scaffold)
 Supply of islet cells (e.g. human, porcine, fish, etc.)  
 Repurposed more likely than new
 Combination more likely than single
 Dual chamber pump that learns & adapts to each person
 Wearable external more likely than subcutaneous 
 Fast acting and responds in real time
 100%  reliable with backup mechanism 
 Stem cell therapy
 Machine-driven reprogramming of cells 
Pharmacology
(Any drug  solution that stops the 
autoimmune attack  and enables beta cell 
regeneration)
(Any mechanism which mimics the function 
of the pancreas with exceptional reliability)
Mechanical Device 
Cell Retraining
(Retraining of cells to produce insulin 
and  stop the autoimmune attack) 
I l  ll l i  
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 i  lection (optimal locati n for tr spla ta ion 
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In 2013, the JDCA reviewed over 300 active type 1 diabetes human clinical trials. The 
overwhelming majority of these trials focus on glucose control, complications, and 
general observations of patient care outcomes. Only six projects have the potential to 
deliver a Practical Cure. A summary of these six trials and their status in 2013 is shown 
in Exhibit 10. 
While the number of Practical Cure research projects in human clinical trials remained 
the same as in 2012, there are some notable updates. The ATG/GCSF project was 
dropped from the list after ATG failed to show a prolonged increase in c-peptide pro-
duction in its phase II clinical trial. We added Viacyte to this year’s list and intend to ac-
tively monitor its ongoing phase I stem cell trial. Among the candidates from last year’s 
list, most are still enrolling or are actively engaged in trials, aside from the LCT/Diabec-
ell announcement that its commercial launch is now expected in 2018, not 2016. 
VII. Practical Cure Research in Human Clinical Trials
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Practical Cure Projects in Human Clinical Trials 
Exhibit 10:
1. A brief representative explanation of the stages of FDA clinical trials: 
Beta cell encapsulation approach that uses 
human islets
Drug combination aimed at both stopping 
the autoimmune attack and stimulating beta 
cell growth
Stem-cell-derived pancreatic cells are encap-
sulated in a drug delivery system implanted 













Commercial launch delayed from 2016 to 2018. 
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encapsulated
Beyond the Practical Cure projects in human clinical trials outlined in Section VII, the 
JDCA has identified several research projects that align with the Practical Cure plat-
forms, but are only in pre-clinical trials at this time. Some of these projects are funded 
by the major non-profits, while others receive support from smaller research centers 
around the world.
Among the major non-profits, only JDRF and the DRIF fund Practical Cure research, 
while the ADA and Joslin do not. The JDRF supports Practical Cure projects at numer-
ous research institutions, whereas the DRIF only funds the Diabetes Research Insti-
tute’s BioHub, which has a stated focus of developing a “biological cure” for type 1 dia-
betes. The BioHub’s holistic, integrated approach to developing a cure across scientific 
platforms is a promising strategy that could be widely replicated across the non-profit 
and research community. However, we still look for improvements in the DRIF’s trans-
parency regarding its actual funding allocations, and the status and prioritization of 
research projects.
Within the smaller research centers, we have identified institutions around the globe 
that are researching Practical Cure solutions across the spectrum of scientific plat-
forms. This list in the exhibit below is not exhaustive; we intend to actively monitor 
these and other emerging programs in the coming year.
State of the Cure 
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The JDCA reviewed over 550 fundraising events in the United States in 2013, including 
all major events organized by the four diabetes non-profits plus major third-party-orga-
nized events. Similar to 2012 levels, cure messaging is used both explicitly and implic-
itly to promote 90% of these fundraising events in 2013, ranging from walks and galas 
to bike rides and golf outings, as shown in Exhibit 12. Among the four non-profits, the 
two biggest fundraisers (JDRF and the ADA) rely the most on cure messaging, at 94% 
and 87% of their events respectively.
Examples of direct messaging include JDRF’s “Walk to Cure Diabetes” and “Ride to Cure 
Diabetes,” or the ADA’s “Tour de Cure” and “Step Out: Walk to Stop Diabetes.” Exam-
ples of implicit messaging includes JDRF’s “Dream Gala,” and “Promise Gala.”
When comparing each organization’s reliance on cure messaging relative to their fund-
ing of cure research, we found a substantial gap between event messaging and funding 
allocations. As shown in Exhibit 13, 90% of total events use the cure message, but only 
18% of overall donations are used to fund cure research. We note that this 18% figure 
is a self-categorized measure of cure research funding, as defined by the non-profits, 
and does not represent funding for a Practical Cure, which we peg at 2% overall.
The next section reviews how corporate governance practices at the non-profits could 
increase accountability for using donor contributions to fund the kind of research do-
nors want to fund. 
IX. Fundraising Methods and Messaging 
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      Events Using Cure Messaging (%)
Exhibit 12:
SOURCE: JDCA Report, “Only 20% of Funds Raised for a Cure Allo-
cated to Cure Research,” Sept 2013
SOURCE: JDCA Report, “Only 20% of Funds Raised for a Cure Allo-
cated to Cure Research,” Sept 2013
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Strong corporate governance, which includes many executive and board level manage-
ment practices, is one of the best indicators of how effectively an organization is run. 
The JDCA recently rated the corporate governance practices of the major non-profits 
after an extensive review of publicly available information and interviews with organi-
zation executives. A summary of the findings and recommendations is presented be-
low (full report at www.thejdca.org).
Our review of corporate governance involves several main areas:  1) strategy and orga-
nization direction; 2) transparency and timelines of communications; 3) accountability 
of management against achievement of objectives; and 4) resource utilization. In a 
for-profit company, the board of directors has a fiduciary duty to ensure that these ar-
eas are executed in a way that is consistent with Securities and Exchange Commission 
guidelines, which were established to protect and uphold the rights of shareholders of 
the company.  
There remains a great opportunity for non-profits to benefit from the governance prac-
tices of for-profit entities. Although non-profit organizations do not have shareholders, 
they do have donors and stakeholders who provide the capital that enables these or-
ganizations to operate. The JDCA advocates that treating the donors as shareholders 
would create a win-win for both parties, changing the relationship between donor and 
non-profit from transactional to collaborative.  
Aggregate Findings
The JDCA’s second annual review of governance concludes that the non-profits’mana-
gerial  practices are substantially below the best practices of public companies. Exhibit 
14 below outlines key learnings in the four STAR ratings areas:
X. Corporate Governance
State of the Cure 
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Summary of STAR Rating 
Exhibit 14:
Publish all financials, annual re-
port, and 990 within 3 months 
of year end. 
Area Finding Suggestions
Strategic Direction





Generally the strongest area
Donor input not generally 
sought before shifts in strategy 
or introduction of new initia-
tives
Few timely reports on progress 
of specific research projects 
versus milestones. Info present-
ed in aggregate, if at all.
Delays in reporting of 990s and 
annual reports
Rewarded more for fundrais-
ing achievements than actual 
progress against a cure
None have a compensation 
program that is directly linked 
to type 1 cure progress
Actual utilization generally not 
aligned with donor interests. 
Majority of contributions not 
actually used for cure research. 
Donors ‘vote’ on major strategic 
shift or new intiative. Publish 
outcome. 
External validation of effective-
ness towards mission. Publish 
outcome.
Publish bi-annual comprehen-
sive research updates. 
Tie performance metrics and 
compensation directly to prog-
ress towards a cure. 
Align broad allocation of budget 
with donor wishes and key 
fundraising promises. Publish 
breakdown of research funding.
You – the readers of this report – are the key to giving us the best chance of reaching a 
Practical Cure in time to change the lives of people now living with type 1. This section 
briefly outlines a few actions that we can all take to make a difference. Please keep in 
mind that the JDCA does not solicit donations for itself and offers this and all of our 
reports throughout the year as a free service to the community.  Our sole purpose is to 
achieve a Practical Cure by 2025. You can help.
The main finding of this report is that despite some promising developments, not 
enough material progress was made toward a Practical Cure during 2013. The bad 
news is that unless we change the paradigm by which research projects are selected, 
funded, and prioritized, we may not see a breakthrough anytime soon. The good news 
is that we can build on the promising developments in 2013. This year we saw the 
launch of the DRI’s BioHub, learned that several smaller research centers are making 
progress on what may be key components of a Practical Cure, and have begun to see 
Practical Cure language seep into the non-profits’ vocabulary. But we need to do more.
Challenging an established approach is never easy, and gaining a priority position for 
Practical Cure research is no exception. But together we can bring about a paradigm 
shift that gives precedence to the pursuit of a Practical Cure.  
Specifically, we can take two significant steps to improve the outlook for a cure: 
Join Voices. By becoming a Juvenile Diabetes Cure Alliance member you add your voice 
to a rapidly growing community of over 10,000 like-minded people who all want to see 
a Practical Cure become a top priority. 
Apply Financial Incentive. Ensure that each donation you make is applied to a Practical 
Cure by attaching a letter to your contribution that stipulates that the funds be used 
solely for Practical Cure research.  A template for stipulations is available at 
www.thejdca.org/donor-tools. There is no more powerful way to accelerate progress 
to a Practical Cure than to specifiy exactly how we want our contributions to be used.
  XI. The Need for Donor Action           
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Cure Donor Advisory Service
The JDCA  provides  a free advisory 
service for donors interested in giving 
with maximum impact.  It covers the 4S’s 
of good giving:
Strategy: 
What are my goals and objectives for 
giving?
Select:  
Given what I want to achieve, who is 
the best recipient for my gift?
Stipulate: 
What is the best way to actual go 
about making my gift?  One year? 
Multi-year? Restricted?  Contingent?
Substantiate:  
Was the my gift actually used as I 





For more information contact 
Cara Murphy
212-308-7433
Cure Donor Advisory Service
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The Juvenile Diabetes Cure Alliance is a non-profit organization that unites individuals who seek a Practical 
Cure for type 1 diabetes by 2025. We work with donors to ensure that their charitable contributions fund 
research with the best chance of delivering a Practical Cure. We conduct independent research that analyzes 
topics related to type 1 cure development with a focus on the four major diabetes non-profits and report our 
findings to Alliance members and the donor community at large.
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14 East 60th St, Suite 208
New York, NY, 10022
Phone: 212-308-7433
Email: info@thejdca.org
Website: thejdca.org
